Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
about
Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.Purification and characterization of a cytosolic Ca(2+)-independent phospholipase A(2) from bovine brain.Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine.Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases.DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.Protective effect of quinacrine against glycerol-induced acute kidney injury in rats.Pharmacological and biochemical interventions of cigarette smoke, alcohol, and sexual mating frequency on idiopathic rat model of Parkinson's disease.The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's diseaseThe role of secretory phospholipase A₂ in the central nervous system and neurological diseases.The proteome of the differentiating mesencephalic progenitor cell line CSM14.1 in vitro.Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease.Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase.Time-course evaluation of whole blood phagocytosis in mice treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion.Impaired nerve conduction velocity in MPTP-treated mouse model of Parkinson's disease.
P2860
Q33565825-2D5F764C-966D-4759-B967-B2FBB9A8AD10Q33652585-1C77F574-A583-4A28-9B17-11B6879614DAQ34004751-41497138-4686-4E27-9C78-F5861342088FQ34976266-EAFBB827-7383-4C1A-BB34-5731D9F65AC3Q35600801-5B3C2711-10C3-4000-BF84-06B28D294246Q36010298-5B8FC496-0412-4E31-9067-B8942D8951C5Q36262805-7CACD2B0-A09D-4216-A9B2-9FCE40D0CD51Q36354808-14BE8830-7CE2-4BF8-89E6-8FD41E0A65FCQ37845675-9DBE6DF7-D5C3-4F3B-8061-D0FFBC0B5F6AQ38151471-40F7CEFC-1012-4B13-9B14-FB9F4C385A22Q39018803-F5FF89A0-E94F-498A-B117-2BF727953A86Q42620778-6D31730B-D849-4849-A5EC-F9DFF68CA6ABQ44392730-E2AB5032-430D-4437-8D0F-3425F5AEC892Q44808668-9F3CA7CD-C52D-42DB-BE13-1A2BAEE62651Q45350888-0739E51F-0015-499A-A90A-F6270A864B47Q48489400-26E332E0-CDDA-4F37-B0F4-93FD77D6CFE1Q48717090-29B4DA81-0D36-47FC-B373-7EC938677509
P2860
Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Protective effect of quinacrin ...... ls of Parkinsonism in rodents.
@ast
Protective effect of quinacrin ...... ls of Parkinsonism in rodents.
@en
type
label
Protective effect of quinacrin ...... ls of Parkinsonism in rodents.
@ast
Protective effect of quinacrin ...... ls of Parkinsonism in rodents.
@en
prefLabel
Protective effect of quinacrin ...... ls of Parkinsonism in rodents.
@ast
Protective effect of quinacrin ...... ls of Parkinsonism in rodents.
@en
P2093
P921
P1476
Protective effect of quinacrin ...... ls of Parkinsonism in rodents.
@en
P2093
P356
10.1016/S0361-9230(00)00427-5
P577
2001-01-01T00:00:00Z